Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Doxepin

Doxepin

Doxepin is a tricyclic antidepressant medication used to treat depression, anxiety, and certain types of chronic pain.
It works by regulating the levels of neurotransmitters in the brain, such as serotonin and norepinephrine, which can help improve mood and reduce symptoms of depression and other mental health conditions.
Doxepin is available in oral capsule and solution formulations and is typically taken once or twice daily.
It is important to follow the dosage instructions carefully and to not suddenly stop taking the medication, as this can lead to withdrawal symptoms.
Doxepin may cause side effects such as drowsiness, dry mouth, constipation, and blurred vision, and it should be used with caution in older adults or those with certain medical conditions.
Reserachers can use PubCompare.ai to optimize their Doxepin research by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy to find the most effective solutions.

Most cited protocols related to «Doxepin»

1
Crystallization of H1R-T4L in Pichia pastoris
Cited 39 times
H1R-T4L was expressed in yeast Pichia pastoris. Ligand binding assays were performed as described in Methods. Pichia pastoris membranes were solubilized using 1% (w/v) n-dodecyl-β-D-maltopyranoside and 0.2% (w/v) cholesteryl hemisuccinate, and purified by immobilized metal ion affinity chromatography (IMAC). After IMAC, the C-terminal GFP was cleaved by Tobacco Etch virus (TEV) protease. Then the sample mixture was passed through IMAC to remove the cleaved His-tagged GFP and TEV protease. Receptor crystallization was performed by lipidic cubic phase (LCP) method. The protein-LCP mixture contained 40% (w/w) receptor solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystals were grown in 40-50 nl protein-laden LCP boluses overlaid by 0.8 μl of precipitant solution (26-30% (v/v) PEG400, 300 mM ammonium phosphate, 10 mM MgCl2, 100 mM Na-citrate pH 4.5 and 1 mM doxepin) at 20 °C. Crystals were harvested directly from LCP matrix and flash frozen in liquid nitrogen. X-ray diffraction data were collected at 100 K with a beam size of 10 × 10 microns on the microfocus beamline I24 at the Diamond Light Source (UK). Data collection, processing, structure solution and refinement are described in Methods.
Shimamura T., Shiroishi M., Weyand S., Tsujimoto H., Winter G., Katritch V., Abagyan R., Cherezov V., Liu W., Han G.W., Kobayashi T., Stevens R.C, & Iwata S. (2011). Structure of the human histamine H1 receptor complex with doxepin. Nature, 475(7354), 65-70.
Publication 2011
ammonium phosphate Biological Assay Cholesterol cholesterol-hemisuccinate Chromatography, Affinity Citrate Crystallization Cuboid Bone Diamond Doxepin Freezing Komagataella pastoris Ligands Lipids Magnesium Chloride Metals monoolein Nitrogen polyethylene glycol 400 Proteins Saccharomyces cerevisiae TEV protease Tissue, Membrane TNFSF14 protein, human X-Ray Diffraction
2
Quantifying Anticholinergic Medication Exposure
Cited 25 times
Medication use was ascertained from GH computerized pharmacy dispensing data that included drug name, strength, route of administration, date dispensed, and amount dispensed for each drug. Anticholinergic use was defined as those medications deemed to have strong anticholinergic activity as per consensus by an expert panel of health care professionals.8 (link),13 (link) Since we were drawing on medication data from as early as 1984 (e.g. extending back 10 years prior to study entry), it was necessary to enhance this contemporary list with medications no longer on the market. Therefore, two clinician/investigators (SLG, JTH) reviewed previously published standard pharmacology/pharmacotherapy reference books to identify additional anticholinergic medications.25 ,26 eTable 1 lists the strong anticholinergic medications according to medication class (e.g., first generation antihistamines, tertiary tricyclic antidepressants, bladder antimuscarinics).
To create our exposure measures, we first calculated the total medication dose for each prescription fill by multiplying the tablet strength by the number of tablets dispensed. This product was then converted to a standardized daily dose (SDD) by dividing by the minimum effective dose per day recommended for use in older adults according to a well-respected geriatric pharmacy reference (eTable 1).27 For each participant, we summed the SDD for all anticholinergic pharmacy fills during the exposure period to create a cumulative total standardized daily dose (TSDD) (see example calculation in eFigure 1). This previously published method allows for standardized conversion of doses of different anticholinergic medications into a single exposure measure so that we are able to capture overall anticholinergic burden.28 (link),29 (link)The primary measure of anticholinergic use was 10-year cumulative exposure (eFigure 2). Prescription fills in the most recent 1 year period were excluded because of concern about protopathic bias.30 (link) Our exposure was time-varying; we assessed 10-year cumulative exposure at study entry and updated the exposure as participants were followed forward in time. We categorized cumulative exposure as no use, 1-90 days, 91-365 days, 366-1095 days, or >1095 days (i.e. >3 years), with cut-points based on clinical interpretability and the exposure distribution observed in our sample. As an example, a person would reach the heaviest level of exposure if they took any of the following medications daily for more than 3 years: oxybutynin 5 mg, chlorpheniramine 4 mg, olanzapine 2.5 mg, meclizine 25 mg or doxepin 10 mg.
Gray S.L., Anderson M.L., Dublin S., Hanlon J.T., Hubbard R., Walker R., Yu O., Crane P, & Larson E.B. (2015). Cumulative Use of Strong Anticholinergic Medications and Incident Dementia. JAMA internal medicine, 175(3), 401-407.
Publication 2015
Aged Anticholinergic Agents Chlorpheniramine Doxepin Health Care Professionals Histamine Antagonists Meclizine Muscarinic Antagonists Olanzapine oxybutynin Pharmaceutical Preparations Pharmacotherapy Tricyclic Antidepressive Agents Urinary Bladder
3
Depression Diagnosis Criteria in FP Clinics
Cited 5 times
Five trained individuals extracted data from randomly selected patient charts at FP clinics. Eligible patient charts included patients ≥35 years of age, who were alive during the study years, living in the provinces of AB or BC during the 2-year period before the study years (2001 and 2004), and who had at least 2 visits to a FP physician during the study years [10 (link)]. Training of the chart reviewers consisted of reviewing ten charts together, and coming to consensus on whether the patient had depression or not based on the definition below. Reviewers extracted other patient information, including demographics, medications, and comorbidities. Comorbid conditions were defined by Quan et al. (2005), and included stroke, dementia, diabetes mellitus, dyslipidemia, coronary artery disease, peripheral vascular disease, congestive heart failure, chronic pulmonary disease, asthma, cancer, chronic kidney disease, hypertension, and dialysis [16 ].
Patients were defined as having depression if the charts stated either that (1) the patient had a Major Depressive Episode (MDE), OR (2) the patient was on antidepressants along with having clinic notes indicating a depressed mood. The antidepressants that were included were as follows: (1) Tricyclic Antidepressants, including amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine, (2) Monoamine Oxidase Inhibitors, including isocarboxazid, phenelzine, and tranylcypromine; (3) Heterocyclics, including amoxapine, buproprion, maprotiline, and trazodone; (4) Selective Serotonin Reuptake Inhibitors, including fluoxetine, paroxetine, and sertraline; (5) Serotonin and Noradrenaline Reuptake Inhibitors, including duloxetine, and venlafaxine; and (6) Noradrenergic and Specific Serotonergic Antidepressants, including mirtazapine. Patient were coded as not having depression if any of the following were stated on the chart: (1) clinic notes indicated that the patient had only a depressed mood (rather than a diagnosis of MDE) but was not taking any of the previously listed medications; (2) patients with only a depressed mood (rather than a diagnosis of MDE) were taking a medication from this list, but it was clearly prescribed for a reason other than depression (e.g. for chronic pain, fibromyalgia, or neuropathic pain); (3) the patient was diagnosed with manic depression; or (4) the patient was diagnosed with bipolar disorder (i.e., manic depression).
Doktorchik C., Patten S., Eastwood C., Peng M., Chen G., Beck C.A., Jetté N., Williamson T, & Quan H. (2019). Validation of a case definition for depression in administrative data against primary chart data as a reference standard. BMC Psychiatry, 19, 9.
Full text: Click here
Publication 2019
Amitriptyline Amoxapine Antidepressive Agents Asthma Bipolar Disorder Cerebrovascular Accident Chronic Kidney Diseases Chronic Pain Clomipramine Congestive Heart Failure Coronary Artery Disease Dementia Desipramine Diabetes Mellitus Dialysis Disease, Chronic Doxepin Duloxetine Dyslipidemias Fibromyalgia Fluoxetine High Blood Pressures Imipramine inhibitors Isocarboxazid Lung Lung Diseases Malignant Neoplasms Maprotiline Mirtazapine Monoamine Oxidase Inhibitors Mood Neuralgia Norepinephrine Nortriptyline Paroxetine Patients Peripheral Vascular Diseases Pharmaceutical Preparations Phenelzine Physicians Protriptyline Selective Serotonin Reuptake Inhibitors Serotonin Sertraline Tranylcypromine Trazodone Tricyclic Antidepressive Agents Trimipramine Venlafaxine
4
Implementation of Universal Perinatal Depression Screening
Cited 5 times
The setting for this study is Kaiser Permanente Northern California, a large group practice within an integrated health care delivery system that provides comprehensive medical services to over 3.6 million members and has approximately 37,000 pregnancies and deliveries in a 14-county region. Kaiser Permanente Northern California employs more than 500 obstetric physicians and nurse practitioners and over 100 Certified Nurse-Midwives. All 15 regional medical centers (with 48 associated office facilities) have Obstetrics and Gynecology, Adult Family Medicine, Pediatric, and Behavioral Medicine/Psychiatry Departments. Coverage is provided for approximately 30% of the northern California population and is similar demographically, racially and ethnically to the population living in the geographic area. Information on diagnoses, procedures, hospitalizations, outpatient visits, laboratory tests, and prescribed medications are maintained within administrative and comprehensive electronic health records (EHR).
From 2009 to 2012, Kaiser Permanente Northern California progressively implemented a universal perinatal depression screening program, with women being screened three times using the Patient Health Questionnaire (PHQ-9): twice during pregnancy (first prenatal visit and 26-28 weeks/the glucola visit) and 3-8 weeks postpartum. Details about the development and implementation of the screening program are described in detail elsewhere13 . Briefly, prior to 2009 women were not screened routinely, generally only if they were symptomatic, but depression diagnoses during pregnancy and postpartum were recorded in the EHR.
In 2009 three medical centers began piloting universal perinatal depression screening with screening during at least of one of three pregnancy and postpartum periods (early pregnancy, late pregnancy andpostpartum). From 2009-2012, referred to as the “roll-out phase”, several guidelines for the program were developed and implemented. Medical assistants asked patients to complete the PHQ-9 form at rooming at the designated visits and the clinician reviewed the form during the visit. If a woman's PHQ-9 score was 10 or higher, the guideline recommendations included symptom assessment and review of related current and past medical history. Using their clinical judgement, if indicated, the clinician documented a depression diagnosis in the EHR for screen positive women. Perinatal Depression Champions and Chiefs were responsible for educating clinicians and staff at the sites. Medical centers developed varying collaborations with Behavioral Health to facilitate referrals for treatment for screen positive women. Over this time the guidelines evolved to include reassessments of women identified with depression with a subsequent PHQ-9 evaluation during a follow-up encounter (office visit, online encounter or telephone visit) within 120 days. By 2010, all medical centers region-wide conducted screening during at least one of the pregnancy and postpartum periods.
By 2012, all obstetric offices in the region had implemented the universal perinatal depression screening program, which included screening at all three time periods, referring for treatment or providing treatment, and conducting follow-up assessments. This is referred to as the Fully-Implemented Phase.
The PHQ-9 has been validated in many studies as an instrument for screening for depression with high sensitivity (> 88%) and specificity (> 88%) in obstetric patients14 (link)-18 (link), as well as a tool to establish depression severity and outcome19 (link). The nine question screener scores range from 0-27. A score of 1-4 suggests minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression and 20-27 suggests severe depression. The PHQ-9 was chosen as the single screening instrument, to enable its use across the obstetric, adult family medicine, and behavioral health departments, knowing that this choice balanced out many factors including scientific validity and feasibility for a large scale population-based screening program.
A population-based retrospective cohort study of pregnant women aged 18 years and older was conducted and included women who had at least one obstetric visit during each of the following three periods of pregnancy and postpartum: the first 20 weeks of pregnancy (early pregnancy), 20 weeks of pregnancy through delivery (late pregnancy), and three months postpartum (postpartum). Inclusion criteria also required the first prenatal visit to occur during one of the three distinct phases in relation to the implementation of the Universal Perinatal Depression Screening Program: 1) Pre-Implementation-first prenatal visit date after April 1, 2007 and birth date prior to January 1, 2009; 2) Roll-out- first prenatal visit date after April 1, 2009 and birth date prior to January 1, 2012; 3) Fully Implemented- first prenatal visit date after April 1, 2012 and birth date prior to October 1, 2014. The timeframes for each phase were established to minimize the possibility of a woman's prenatal and postpartum visits crossing two phases and confounding the ability to attribute results to one phase. If a woman had more than one pregnancy during the study period, only the first pregnancy was included to avoid non-independent observations. The final study population included 97,678 pregnant women. This study was approved by the Kaiser Permanente Northern California Institutional Review Board.
Women were considered to have a new depression diagnosis if they had at least one depression ICD-9 diagnosis codes (296.20-296.25, 296.30 - 296.35, 298.0, 300.4, 309.0, 309.1, 648.4, or 311) during pregnancy or up to three months after delivery and no depression diagnosis or antidepressant drug dispensing in the year prior to their last menstrual period. Treatment for a new depression diagnosis was defined as having at least one antidepressant medication dispensed or at least one individual counseling visit or attendance at a group class that occurred on the same date or after the new depression diagnosis through 6 months postpartum. Antidepressant medications were predominantly SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline) but also included tricyclic acids (amitriptyline, clomipramine, desipramine, nortriptyline, doxepin, imipramine, protriptyline, and trimipramine), SNRIs (desvenlafaxine, duloxetine, milnacipran, and venlafaxine), monoamine oxidase inhibitors (phenelzine and tranylcypromine), and others (trazodone, bupropion, atomoxetine, mirtazapine, nefazodone, and vilazodone).
Data on maternal demographic and socioeconomic characteristics including age at delivery, marital status, race/ethnicity, and Medicaid status during pregnancy, as well as previous mental health diagnoses any time prior to their last menstrual period were ascertained.
Data are reported as frequencies and percentages. Tests of trend were conducted to compare overall PHQ-9 screening rates, and rates of depression diagnoses across each of the three phases of the universal perinatal depression screening program (Pre-Implementation, Roll-Out and Fully-Implemented) while chi-square tests were used to compare PHQ-9 scores (<10, 10-14, 15+) and screening rates for each pregnancy and postpartum period (i.e., early pregnancy, late pregnancy, and postpartum). Treatment rates and type of treatment received were also compared across the three phases of the program, for all women with a depression diagnosis and separately for women with a PHQ-9 score of 15 or greater indicating moderately severe to severe depression. Additional analyses were conducted to address limitations in comparing the percentage of women receiving treatment across the phases including: 1) the increasing number of women in each phase, 2) under ascertainment of depression diagnoses prior to the screening program and thus a smaller number of women identified as needing treatment, 3) the potential that women diagnosed with depression prior to the screening program were more severe. Under the assumption that the screening program more accurately identified the true percentage of women with depression in the population, the percentage of women with depression in the Fully-Implemented phase was used to calculate the expected number women with depression in the other two phases. An expected percentage of treatment was then calculated using the observed number of women in treatment as the numerator and the expected number of women with a depression diagnosis in the denominator (Pre-Implementation and Roll-out Phases). This was conducted for both new depression diagnosis and new depression diagnosis and PHQ-9 score of 15 or greater. A Cochran-Armitage test for trend was conducted.
Improvement in depressive symptoms was assessed within each phase of the program through three metrics: 1) the percentage of women whose PHQ-9 score improved by 50% or more; 2) the percentage of women with a final PHQ-9 score less than 10; and 3) the percentage of women with a 5-point or greater drop in PHQ-9 score from the highest PHQ-9 to the final PHQ-9 score up to 180 days postpartum, which was considered to indicate clinical improvement19 (link),20 (link). Improvement in depressive symptoms was evaluated overall and separately for women with high severity (PHQ-9 score of 15 or greater).
Additional Chi-square analyses were conducted using the Fully-Implemented Phase to address potential bias. First we compared women in our sample to women excluded due to not having a prenatal or postpartum visit during all three time periods. Among women with a depression diagnosis or PHQ-9 scores of 15 or greater, we also compared those with a follow-up PHQ-9 to those without. Analyses were performed using SAS 9.3 (Cary, NC, USA; 2012).
Avalos L.A., Raine-Bennett T., Chen H., Adams A.S, & Flanagan T. (2016). Improved Perinatal Depression Screening, Treatment, and Outcomes With a Universal Obstetric Program. Obstetrics and gynecology, 127(5), 917-925.
Publication 2016
Acids Adult Amitriptyline Antidepressive Agents Atomoxetine Bupropion Childbirth Citalopram Clinical Reasoning Clomipramine Depressive Symptoms Desipramine Desvenlafaxine Diagnosis Doxepin Duloxetine Escitalopram Ethics Committees, Research Ethnicity Fluoxetine Fluvoxamine Glucola Hospitalization Hypersensitivity Imipramine Menstruation Mental Health Milnacipran Mirtazapine Monoamine Oxidase Inhibitors Mothers nefazodone Nortriptyline Nurse Midwife Obstetric Delivery Office Visits Outpatients Paroxetine Patients Pharmaceutical Preparations Phenelzine Physicians Population Programs Practitioner, Nurse Pregnancy Pregnant Women Protriptyline Selective Serotonin Reuptake Inhibitors Sertraline SNRIs Symptom Assessment Tranylcypromine Trazodone Trimipramine Venlafaxine Vilazodone Woman
5
High-Throughput Virtual Screening of H1R Ligands
Cited 4 times
All virtual screenings were performed by docking program PLANTS (version 1.1)27 . PLANTS combines an ant colony optimization algorithm with an empirical scoring function30 (link) for the prediction and scoring of binding poses in a protein structure. For each compound, 25 poses were calculated and scored by the chemplp scoring function at speed setting 2. The binding pocket of H1R was defined by the coordinates of the center of co-crystallized doxepin in the 3RZE structure and a radius of 10.8 Å (which is the maximum distance from the center defined by a 5 Å radius around doxepin). All other options of PLANTS were left at their default setting.
de Graaf C., Kooistra A.J., Vischer H.F., Katritch V., Kuijer M., Shiroishi M., Iwata S., Shimamura T., Stevens R.C., de Esch I.J, & Leurs R. (2011). Crystal structure-based virtual screening for novel fragment-like ligands of the human histamine H1 receptor. Journal of medicinal chemistry, 54(23), 8195-8206.
Publication 2011
Doxepin Plants Radius Rumex Screening Staphylococcal Protein A

Most recents protocols related to «Doxepin»

1
Controlling Confounding Factors in GERD Analysis
To control for potential confounding factors in the analyses, covariates were identified based on previous studies, expert opinion, and covariate availability within the data. The covariates used in this study included age, sex, household income, region of residence, disability, Charlson comorbidity index (CCI) score, smoking status, body mass index (BMI), co-medications, and baseline year.
The age groups were classified using 10-year intervals. A total of eight groups aged ≥20 years old were included. The household income groups initially provided with 11 classes (class 0, lowest income; class 10, highest income) from the NHIS database were recategorized into three groups (low, class 0–2; medium, class 3–7; high, class 8–10). The region of residence was recategorized into urban (Seoul, Busan, Daegu, Incheon, Gwangju, Daejeon, and Ulsan) and rural (Gyeonggi, Gangwon, Chungcheongbuk, Chungcheongnam, Jeollabuk, Jeollanam, Gyeongsangbuk, Gyeongsangnam, and Jeju). The patients’ CCI scores were estimated from their disease records using previously validated algorithms [25 (link)]. Smoking status was categorized as current smoker, ex-smoker, and never smoked. BMI was calculated as an individual’s body weight in kilograms divided by their height in meters squared (kg/m2). In this study, BMI was categorized into underweight (BMI less than 18 kg/m2), normal (BMI between 18 to 25 kg/m2), and overweight (BMI more than 25 kg/m2). Co-medications, such as calcium channel blockers (amlodipine, felodipine, flunarizine, isradipine, levamlodipine, nicardipine, nifedipine, nimodipine, nisoldipine, diltiazem, and verapamil), antidepressants (amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, and trimipramine), theophylline, and anticholinergic drugs (benztropine, dicyclomine, hyoscyamine, isopropamide, and scopolamine), which are known to contribute to the development of GERD, were also considered as covariates if the medication was used for more than 60 days between the index date and the last observation date.
Lee S.W., Park J., Kim H., Jung Y.W., Baek Y.S., Lim Y, & Kim K. (2023). Atopic dermatitis and risk of gastroesophageal reflux disease: A nationwide population-based study. PLOS ONE, 18(2), e0281883.
Full text: Click here
Publication 2023
Age Groups Amitriptyline Amlodipine Amoxapine Anticholinergic Agents Antidepressive Agents Benztropine Body Weight Calcium Channel Blockers Clomipramine Desipramine Dicyclomine Diltiazem Disabled Persons Doxepin Ex-Smokers Felodipine Flunarizine Gastroesophageal Reflux Disease Households Hyoscyamine Imipramine Index, Body Mass Isradipine levamlodipine Maprotiline National Health Insurance Nicardipine Nifedipine Nimodipine Nisoldipine Nortriptyline Patients Pharmaceutical Preparations Protriptyline Scopolamine Theophylline Trimipramine Verapamil
2
Reproductive-Age Women's Reproductive Health
The statistical population of this descriptive-analytic cross-sectional study included 400 non-pregnant or reproductive age (15–49 years) visiting health centers of Tabriz, Iran from October 2021 to December 2022.
The inclusion criteria were as follows: being of the reproductive age (15–49 years), being married and having no pregnancy diagnosed during research. Furthermore, the exclusion criteria were as follows: having a history of recent urinary tract infection, having a history of gynecological surgery (e.g., reconstructive and cosmetic surgeries), taking tricyclic antidepressants (e.g., amitriptyline, clomipramine, dosulepin, doxepin, imipramine, lofepramine, nortriptyline, and trazodone), selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, paroxetine, and sertraline), monoamine oxidase (e.g., phenelzine and tranylcypromine), and reuptake inhibitor of serotonin and noradrenaline (e.g., reboxetine and venlafaxine), experiencing any stressful events (e.g., divorce, death of a first-degree relative, and diagnosis of an incurable disease for a first-degree relative in the past three months), and experiencing a childbirth in the past six months.
Rashidi F, & Mirghafourvand M. (2023). Pelvic floor disorder and relevant factors in Iranian women of reproductive age: a cross-sectional study. BMC Women's Health, 23, 71.
Full text: Click here
Publication 2023
Amitriptyline Birth Citalopram Clomipramine Diagnosis Dothiepin Doxepin Fluoxetine Gynecologic Surgical Procedures Imipramine Lofepramine Monoamine Oxidase Norepinephrine Nortriptyline Paroxetine Phenelzine Pregnancy Reboxetine Reconstructive Surgical Procedures Reproduction Selective Serotonin Reuptake Inhibitors Serotonin Uptake Inhibitors Sertraline Tranylcypromine Trazodone Tricyclic Antidepressive Agents Urinary Tract Infection Venlafaxine
3
Validated LC-MS/MS Method for Psychotropic Drugs
All solvents used were LC–MS grade, Baker Analyzed, with a purity > 99.9% (obtained from VWR) that included water, acetonitrile, and methanol used in the preparation of calibrators, and operation of the LC–MS/MS. The primary analytes (in the form of certified reference material) were all purchased from Cerilliant Corporation (Round Rock, TX, USA). The analytes used were: Bupropion (BUP B-034), Citalopram (CIT C-095), Desipramine (DES D-906), Imipramine (IMI I-902), Milnacipran (MLN M-209), Olanzapine (OLN O-024), Sertraline (SRT S-021), Vilazodone (VIL (V-076), and the desired internal standards for the analytes were: Fluoxetine D-6 (FLU-D6 F-038), Citalopram D-6 (CIT-D6 C-090), Mirtazapine D-3 (MRT-D3 M-191), Clomipramine D-3 (CLO-D3 C-116), Doxepin (DOX-D3 D-060), Milnacipran D-10 (MLN-D10 M-149), Buproprion (BUP-D9 B-052), Vilazodone D-4 (VIL-D4 (V-028). Reagent-grade formic acid (96% pure) was purchased from Fisher Scientific to improve ion mobility on the mobile phases. Ultra-low steroid, drug-depleted DDC Mass Spect Gold Serum was purchased from Sigma-Aldrich and was used as the base matrix to create the calibrators and Quality Controls (QCs). Sodium Azide (≥ 99.5%, ReagentPlus) was purchased from Sigma-Aldrich (used as a preservative).
Fariha R., Deshpande P.S., Rothkopf E., Jabrah M., Spooner A., Okoh O.D, & Tripathi A. (2023). An in-depth analysis of four classes of antidepressants quantification from human serum using LC–MS/MS. Scientific Reports, 13, 2115.
Full text: Click here
Publication 2023
acetonitrile Bupropion Citalopram Clomipramine Desipramine Doxepin Fluoxetine formic acid Gold Imipramine Methanol Milnacipran Mirtazapine Olanzapine Pharmaceutical Preparations Pharmaceutical Preservatives Range of Motion, Articular Sertraline Serum Sodium Azide Solvents Steroids Tandem Mass Spectrometry Tomography, Emission-Computed, Single-Photon Vilazodone
4
Validating Psychiatric Diagnoses in UK Biobank
Diagnoses of anxiety and depression were retrieved from the UK Biobank hospital inpatient data (according to ICD-10 codes) [18 ] and primary care data (according to SNOMED CT, local EMIS codes, Clinical Terms Version 3, and Local TPP codes) [19 ]. The diagnoses of psychiatric disorders from HES in England have been validated, indicating a positive predictive value of up to 75% for depression and <60% for anxiety [20 (link)]. Prescription of psychotropic medications was ascertained through mapping the UK Biobank prescription codes (i.e., dm+d and local EMIS codes) to their corresponding active ingredients using dm+d XML Transformation Tool and UK Biobank Data-Coding 7678 resource [19 ]. The active ingredients were then matched to the WHO Atomical Therapeutic Chemical (ATC) classification system [21 ], and the ingredients (e.g., doxepin, esketamine) with more than one matched ATC codes were discarded as it is difficult to disentangle therapeutic targets. We extracted information (i.e., prescription code and date) about anxiolytics (N05B) and antidepressants (N06A) in the analysis. Supplementary Table S1 provides a list of the active ingredients and their corresponding ATC codes used in this study.
Wang Y., Ge F., Wang J., Yang H., Han X., Ying Z., Hu Y., Sun Y., Qu Y., Aspelund T., Hauksdóttir A., Zoega H., Fang F., Valdimarsdóttir U.A, & Song H. (2023). Trends in incident diagnoses and drug prescriptions for anxiety and depression during the COVID-19 pandemic: an 18-month follow-up study based on the UK Biobank. Translational Psychiatry, 13, 12.
Full text: Click here
Publication 2023
Anti-Anxiety Agents Antidepressive Agents Anxiety Disorders Diagnosis Doxepin Esketamine Inpatient Mental Disorders Prescription Drugs Primary Health Care Psychotropic Drugs Therapeutics
5
Topical Anesthesia for Neuropathic Cancer Pain
We conducted a prospective, open-label, single-arm study for pain control. A total of 96 terminal cancer patients with stage IV (advanced) malignant disease who were admitted to the hospice ward at National Cheng Kung University Hospital (NCKUH), were enrolled. The eligibility criteria were 18 years of age and above, male or female, who were treated with opioids for cancer-related pain and still experiencing neuropathic cancer pain evaluated by the LANSS Pain Scale [14 (link)]. In addition to neuropathic pain, the pain had to be well localized, superficial, and involve positive symptoms such as allodynia, raised pin-prick threshold, and hyperalgesia. Regardless of the intensity, all patients with such neuropathic pain were included. There was no contraindication to topical anesthetic application. The study period was 3 days, and all participants signed informed consent forms. Patient symptoms were evaluated by questionnaires, including an 11-point pain intensity scale, a 5-item pain relief score, and 5-item analgesic treatment quality. The exclusion criteria included the following: (1) skin lesions with bacterial infection and allergies to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.); (2) a significant concomitant illness that the investigator believed would interfere with the evaluation of the study medications, including lidocaine, tocainide, mexiletine, and phenytoin; and (3) the patient received treatment with topically applied medication (e.g., lidocaine/prilocaine cream, capsaicin cream, and doxepin cream) 72 hours before the study. The National Cheng Kung University Hospital institutional review board approved this study (BR-100-005-C).
Tsai J.H., Liu I.T., Su P.F., Huang Y.T., Chiu G.L., Chen Y.Y., Lai W.S, & Lin P.C. (2023). Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. BMC Palliative Care, 22, 4.
Full text: Click here
Publication 2023
4-Aminobenzoic Acid Allodynia Analgesics Benzocaine BR 100 Cancer Pain Capsaicin derivatives Doxepin Eligibility Determination Ethics Committees, Research Hospice Care Hyperalgesia Hypersensitivity Lidocaine Males Malignant Neoplasms Management, Pain Mexiletine Neuralgia Opioids Pain Patients Pharmacotherapy Phenytoin Prilocaine, Lidocaine Procaine Severity, Pain Skin Diseases, Bacterial Tetracaine Tocainide Topical Anesthetics Woman

Top products related to «Doxepin»

1
Doxepin by Merck Group
Sourced in United States
Doxepin is a laboratory equipment product manufactured by Merck Group. It is a tricyclic compound used in various research and analytical applications. The core function of Doxepin is to serve as a reference standard or a chemical reagent in laboratory settings. No further details or interpretations are provided.
2
Sodium hydroxide (naoh) by Merck Group
Sourced in Germany, United States, India, United Kingdom, Italy, China, Spain, France, Australia, Canada, Poland, Switzerland, Singapore, Belgium, Sao Tome and Principe, Ireland, Sweden, Brazil, Israel, Mexico, Macao, Chile, Japan, Hungary, Malaysia, Denmark, Portugal, Indonesia, Netherlands, Czechia, Finland, Austria, Romania, Pakistan, Cameroon, Egypt, Greece, Bulgaria, Norway, Colombia, New Zealand, Lithuania
Sodium hydroxide is a chemical compound with the formula NaOH. It is a white, odorless, crystalline solid that is highly soluble in water and is a strong base. It is commonly used in various laboratory applications as a reagent.
3
Puromycin by Meilun
Sourced in China
Puromycin is a laboratory reagent commonly used in molecular biology and cell culture experiments. It is an antibiotic that inhibits protein synthesis by interfering with the translation process. Puromycin is often used as a selection marker in genetic engineering to identify and select for cells that have successfully incorporated a gene of interest.
4
Sars cov 2 spike pseudovirus by Sino Biological
Sourced in China
The SARS-CoV-2 spike pseudovirus is a laboratory tool designed to mimic the structure and behavior of the SARS-CoV-2 virus spike protein. It is used for research and testing purposes in controlled environments.
5
Isopropyl alcohol by Merck Group
Sourced in United States, Germany, India, United Kingdom, China, Italy, Argentina, Sao Tome and Principe
Isopropyl alcohol is a colorless, flammable liquid that is commonly used as a cleaning agent and disinfectant in laboratory settings. It has a chemical formula of C3H8O and a boiling point of approximately 82°C. Isopropyl alcohol is effective in removing grease, oil, and other contaminants from surfaces and equipment.
6
One touch glucose meter by LifeScan
Sourced in United States
The OneTouch glucose meter is a portable medical device used to measure and monitor blood glucose levels. It provides a quick and convenient way for individuals to check their blood sugar levels. The device requires a small blood sample, typically obtained from the fingertip, and displays the glucose reading on its digital display.
7
Acetonitrile by Merck Group
Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia
Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.
8
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
9
Discovery studio software by Dassault Systèmes
Sourced in United States
Discovery Studio is a comprehensive software platform for structure-based drug design. It provides tools for protein modeling, ligand docking, virtual screening, and data analysis to support drug discovery research. The software offers a range of functionalities to assist scientists in the exploration and analysis of molecular structures and interactions.
10
Milli q plus system by Merck Group
Sourced in United States, Germany, France, Spain, Italy, United Kingdom
The Milli-Q Plus system is a water purification system designed to produce high-quality ultrapure water for laboratory applications. It utilizes a multi-stage purification process to remove various contaminants and impurities from the input water source, resulting in a consistent and reliable supply of purified water meeting the highest industry standards.

More about "Doxepin"

Doxepin is a tricyclic antidepressant medication that has been widely used to treat a variety of mental health conditions, including depression, anxiety, and certain types of chronic pain.
This versatile drug works by regulating the levels of key neurotransmitters in the brain, such as serotonin and norepinephrine, which can help improve mood and alleviate symptoms.
Doxepin is available in oral capsule and solution formulations, and is typically taken once or twice daily.
It's important to carefully follow the dosage instructions and not suddenly stop taking the medication, as this can lead to withdrawal symptoms.
Doxepin may cause side effects such as drowsiness, dry mouth, constipation, and blurred vision, and should be used with caution in older adults or those with certain medical conditions.
Researchers can utilize powerful tools like PubCompare.ai to optimize their Doxepin research by locating the best protocols from literature, pre-prints, and patents.
This AI-driven approach can enhance reproducibility and accuracy, ensuring that researchers find the most effective solutions for their Doxepin-related studies.
When exploring Doxepin research, researchers may also encounter related terms and compounds, such as Sodium hydroxide, Puromycin, SARS-CoV-2 spike pseudovirus, Isopropyl alcohol, One Touch glucose meter, Acetonitrile, Formic acid, and Discovery Studio software.
By understanding the connections between these various elements, researchers can gain a more comprehensive understanding of the Doxepin landscape and develop more informed and effective research strategies.
Ultimately, the versatility and importance of Doxepin in the treatment of mental health conditions, coupled with the powerful tools and resources available to researchers, make this a fascinating and highly relevant area of study.
With the right approach and the support of cutting-edge technologies like PubCompare.ai, researchers can unlock new insights and drive forward the field of Doxepin research.